The next generation of therapeutics for chronic kidney disease

Abstract

Current treatments for chronic kidney disease (CKD) only delay disease progression and can be associated with significant side effects. Here, Suzstak and Breyer discuss emerging novel targets and strategies for the treatment of CKD. Key challenges faced in the development of CKD therapies and future clinical trial designs are considered. Chronic kidney disease (CKD) represents a leading cause of death in the United States. There is no cure for this disease, with current treatment strategies relying on blood pressure control through blockade of the renin–angiotensin system. Such approaches only delay the development of end-stage kidney disease and can be associated with serious side effects. Recent identification of several novel mechanisms contributing to CKD development — including vascular changes, loss of podocytes and renal epithelial cells, matrix deposition, inflammation and metabolic dysregulation — has revealed new potential therapeutic approaches for CKD. This Review assesses emerging strategies and agents for CKD treatment, highlighting the associated challenges in their clinical development.